Lilly's Donanemab Gets Positive CHMP Opinion In Early Symptomatic Alzheimer's Disease
25/7 12:54
(RTTNews) - Eli Lilly and Company (LLY) Friday said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for donanemab for the treatment of early symptomatic Alzheimer's disease....